Valuation: Iterum Therapeutics plc

Market Cap 52 46.2 43.12 39.3 74.13 5K 74.82 521.85 202.22 2.56K 195.23 191 8.2K P/E 2025 *
-
P/E 2026 * -
Enterprise Value 52 46.2 43.12 39.3 74.13 5K 74.82 521.85 202.22 2.56K 195.23 191 8.2K EV / Sales 2025 *
-
EV / Sales 2026 * -
Free-Float
99.22%
Yield 2025 *
-
Yield 2026 * -
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0.39
1 year 0
Extreme 1.0E-6
0.83
3 years 0
Extreme 1.0E-6
3.02
5 years 0
Extreme 1.0E-6
11.25
10 years 0
Extreme 1.0E-6
195
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 30/09/2016
Chief Tech/Sci/R&D Officer - 30/06/2017
Corporate Officer/Principal 58 29/06/2025
Director TitleAgeSince
Chairman 65 09/03/2025
Director/Board Member 67 21/12/2020
Director/Board Member 62 11/03/2021
Date Insider Type Main position Quantity % Market Cap. Importance
18/11/25 Buy

Founder

6,000 0.0125%
08/08/25 Buy

Founder

15,000 0.0356%
01/07/25 Free

Executive/Senior Manager

200,000 0.5783%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 52
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.20%-0.53%+52.63%+128.54% 39.05B
Weighted average by Cap. +0.12%-0.84%+56.96%+138.26%

Financials

2025 *2026 *
Net sales 800K 711K 663K 605K 1.14M 76.91M 1.15M 8.03M 3.11M 39.32M 3M 2.94M 126M 10M 8.88M 8.29M 7.56M 14.26M 961M 14.39M 100M 38.89M 491M 37.54M 36.73M 1.58B
Net income -31.4M -27.9M -26.04M -23.73M -44.76M -3.02B -45.18M -315M -122M -1.54B -118M -115M -4.95B -11.2M -9.95M -9.29M -8.47M -15.97M -1.08B -16.11M -112M -43.55M -550M -42.05M -41.14M -1.77B
Net Debt - -
Logo Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (oral sulopenem) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections (uUTIs) caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belongs to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Employees
9
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.000001
Average target price
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ITRMF Stock